funder-graph

FundersNY

Grants paid by Fund for Ophthalmic Knowledge Inc C/O David H Abramson Md

EIN 13-4171637 · New York, NY · Form 990, Schedule I · NTEE A12

Fund for Ophthalmic Knowledge Inc C/O David H Abramson Md of New York, NY (EIN 13-4171637) reported 8 grants paid totaling $1,245,812 to 1 recipient in tax years 2018–2024, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.

Grants paid

$1,245,812

8 grants

Recipients

1

distinct organizations

Tax years

2018–2024

7 filings in the corpus

By tax year

Grants by tax year, as the same figures
Tax yearGrants paidAmount paidApproved for future
20181$206,960
20192$409,608
20201$157,056
20211$56,184
20221$161,184
20231$198,692
20241$56,128

Top recipients

The 1 recipients receiving the most from Fund for Ophthalmic Knowledge Inc C/O David H Abramson Md, by grants paid, out of 1 distinct recipient.

Recipients ranked by total grants paid
RecipientMatchLocationGrantsTotal paidLatest year
Memorial Sloan Kettering Cancer Center 13-1624182ANew York, NY8$1,245,8122024

Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.

Every grant

All 8 grant rows this organization reported, most recent first.

Grants reported by Fund for Ophthalmic Knowledge Inc C/O David H Abramson Md
Tax yearRecipientMatchAmountTypePurposeSource filing
2024Memorial Sloan Kettering Cancer Center New York, NYA$56,128paidSUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.202543109349303024
2023Memorial Sloan Kettering Cancer Center New York, NYA$198,692paidSUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.202421379349300537
2022Memorial Sloan Kettering Cancer Center New York, NYA$161,184paidSUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.202301309349302280
2021Memorial Sloan Kettering Cancer Center New York, NYA$56,184paidSUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.202211369349304031
2020Memorial Sloan Kettering Cancer Center New York, NYA$157,056paidSUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.202133089349301718
2019Memorial Sloan Kettering Cancer Center New York, NYA$204,804paidSUPPORTED BASIC AND CLINICAL RESEARCH IN CANCER PERFORMED AT MSKCC AND RESULTING IN MORE THAN 15 PEER REVIEWED SCIENTIFIC PUBLICATIONS.202023189349302822
2019Memorial Sloan Kettering Cancer Center New York, NYA$204,804paidSUPPORTED BASIC AND CLINICAL RESEARCH IN CANCER PERFORMED AT MSKCC AND RESULTING IN MORE THAN 15 PEER REVIEWED SCIENTIFIC PUBLICATIONS.202023189349302822
2018Memorial Sloan Kettering Cancer Center New York, NYA$206,960 + $8,835 non-cashpaidMEMORIAL SLOAN-KETTERING CANCER CENTER ("MSKCC") ($215,795) -A) SUPPORT THE RESEARCH AND CLINICAL STUDIES FOR RETINOBLASTOMA ($150,000): THESE FUNDS SUPPORTED THE RESEARCH CONDUCTED AT MSK DURING THE YEAR. IT RESULTED IN 16 PUBLICATIONS IN PEER REVIEWED JOURNALS INCLUDING THE BRITISH JOURNAL OF OPHTHALMOLOGY, OPHTHALMOLOGY, AMERICAN JOURNAL OF OPHTHALMOLOGY, NEOPLASIA, PLOS1, INT J OF RETINA AND VITREOUS, JAMA OPHTHALMOLOGY, OPHTHALMIC GENETICS AND IOVS. THE TOTAL NUMBER OF AUTHORS SUPPORTED BY THESE FUNDS IN 2018 WAS 52.B) CYCLE FOR SURVIVAL ($55,000): DONATION TO THE CYCLE CHARITY-THE YEARLY FUND RAISER AT MSK TO SUPPORT RESEARCH IN RARE CANCERS.C) RESEARCH EQUIPMENT AND SUPPLIES ($10,795): COMPUTERS, STATISTICIANS, REPRINTS, PRODUCTION OF SCIENTIFIC ARTICLES AND ONGOING RESEARCH AT MSK, INCLUDING CHARGES BY LABS FOR PROCESSING SPECIMENS FOR RESEARCH.201912049349301056

Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.

Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.

Source filings

Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.

Returns this page is derived from
FormTax yearPeriod endFiledSchemaIRS OBJECT_ID
99020242024-12-31not stated2024v5.2202543109349303024
99020232023-12-31not stated2023v5.0202421379349300537
99020222022-12-31not stated2022v5.0202301309349302280
99020212021-12-31not stated2021v4.2202211369349304031
99020202020-12-31not stated2020v4.1202133089349301718
99020192019-12-31not stated2019v5.1202023189349302822
99020182018-12-31not stated2018v3.1201912049349301056

Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/134171637.json.

The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.

This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.